ARTHEx Biotech SL is a clinical-stage biotechnology company based in Valencia, Spain, specializing in the development of targeted RNA medicines designed to modulate gene expression for rare genetic neuromuscular disorders. The company's lead program, ATX-01, is currently in clinical evaluation for myotonic dystrophy type 1 (DM1) and employs a unique mechanism to inhibit microRNA23b, thereby restoring MBNL protein function. ARTHEx is also advancing a pipeline of therapies targeting high unmet needs in muscular, central nervous system, cardiac, and pulmonary diseases, utilizing its proprietary platform for selective oligonucleotide delivery to specific tissues.